{
    "pmcid": "10683510",
    "qa_pairs": {
        "How can nanobodies be advantageous in targeting the SARS-CoV-2 Spike protein?": [
            "They can access epitopes less accessible to conventional antibodies.",
            "They are larger and more stable than conventional antibodies.",
            "They can only target the S2 subunit of the Spike protein.",
            "They are ineffective against conserved regions across variants."
        ],
        "How do mutations in the Omicron variant affect the Spike protein's interaction with hACE2?": [
            "Enhance binding affinity and contribute to immune escape.",
            "Decrease the stability of the Spike protein.",
            "Reduce the prevalence of the open conformation.",
            "Inhibit the formation of the six-helix bundle (6-HB)."
        ],
        "What is the role of the S2 subunit in the SARS-CoV-2 Spike protein?": [
            "Facilitates membrane fusion, a critical step for viral entry.",
            "Contains the receptor-binding domain (RBD) for binding to hACE2.",
            "Undergoes cleavage by furin and TMPRSS2 for activation.",
            "Stabilizes the closed conformation of the Spike protein."
        ],
        "What is the significance of the D614G mutation in the Spike protein?": [
            "Increases the prevalence of the open conformation, enhancing infectivity.",
            "Decreases the binding affinity to hACE2.",
            "Prevents cleavage at the S1/S2 site by furin.",
            "Stabilizes the closed conformation, reducing viral entry."
        ],
        "What therapeutic strategy involves designing nanobodies to stabilize specific conformations of the Spike protein?": [
            "Preventing the transition to the open state necessary for receptor binding.",
            "Enhancing the cleavage at the S1/S2 site by furin.",
            "Increasing the prevalence of the prebinding state.",
            "Facilitating the formation of the six-helix bundle (6-HB)."
        ]
    }
}